CD8A and colorectal cancer: Reflecting the superior quantity, quality, persistence, and antitumor efficacy of vaccine-induced CD8+ T-cell responses, all of which are important factors to protect colorectal cancer patients from recurrent and/or metastatic disease, this combination may produce significantly better clinical efficacy in patients than either single agent.